Subsequent Manufacturing Technology Transfer. No later than [***] months prior to the completion of the first Proof of Concept Clinical Trial for a Licensed Product (or earlier, at Gilead’s option), Hookipa shall: (a) provide access to Gilead or its designee to copies of all Hookipa Know-How and other Know-How as of the date of transfer that is necessary or reasonably useful for Gilead, or its designee, to Manufacture such Licensed Product; and (b) assign (to the extent requested by Gilead) to Gilead any contract manufacturing agreements with any Third Party contract manufacturer relating to such Licensed Product; provided, that, to the extent the services provided under any contract manufacturing agreements existing and in effect as of the Effective Date are also for products other than such Licensed Product, Hookipa shall use commercially reasonable efforts to promptly amend or otherwise modify such agreements so that such agreements can be assigned to Gilead as contemplated hereunder. In addition, upon written request of Gilead, Hookipa shall provide to Gilead or its designee consultation and technical assistance as reasonably requested for Gilead to Manufacture, itself or through a Third Party, such Licensed Product. Gilead shall reimburse Hookipa at the FTE Rate for the documented costs of any FTEs and Out-of-Pocket Costs reasonably incurred by Hookipa in carrying out such transfer(s), consultation, and assistance within [***] days after Gilead’s receipt of an invoice therefore from Hookipa.
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, if Ablynx makes any invention, discovery, or improvement relating to the Manufacture of a Licensed Compound or a Licensed Product during the Term, Ablynx shall promptly disclose such invention, discovery, or improvement to AbbVie, and shall, at AbbVie’s request, perform a technology transfer with respect to such invention, discovery, or improvement in the same manner as provided in Section 4.7.2.
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, in the event that Xxxxxxx or any of its Affiliates makes any invention, discovery or improvement relating to the Manufacture of a Licensed Compound or a Licensed Product during the Term, Xxxxxxx shall promptly disclose such invention, discovery or improvement to Forest, and shall, at Forest’s request and expense, perform technology transfer with respect to such invention, discovery or improvement in the same manner as provided in Section 5.3; provided, however, that this Section 5.4 shall not apply to any invention, discovery or improvement owned or otherwise controlled by a Person that becomes a Controlling Affiliate after the Effective Date if such invention, discovery or improvement (a) existed before such Person became a Controlling Affiliate of Xxxxxxx, (b) is not specific to the Manufacture of a Licensed Compound or Licensed Product and (c) was developed without the use of any Xxxxxxx Know-How or any other Information generated under or in connection with this Agreement, including any Product Information or Confidential Information of Forest.
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing or Section 7.1, if Galapagos makes any Improvement relating to the Manufacture of a Molecule or Product during the Term after the initial technology transfer pursuant to Section ***Confidential Treatment Requested***
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, in the event that Lexicon or any of its Affiliates generates any material additional Lexicon Know-How relating to, or that is otherwise necessary or useful for, the Manufacture of the Licensed Compound or a Licensed Product during the Term, Lexicon shall promptly disclose such Lexicon Know- Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. How to Sanofi and shall, at Sanofi’s request, perform technology transfer with respect to such Lexicon Know-How in the same manner as provided in Section 6.2.
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, if Galapagos makes any invention, discovery, or improvement relating to the Manufacture of a Licensed Compound or a Licensed Product during the Term, Galapagos shall promptly disclose such invention, discovery, or improvement to Xxxxxx, and shall, at Xxxxxx’x request, perform technology transfer with respect to such invention, discovery, or improvement in the same manner as provided in Section 4.8.2.
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing or the licenses and other rights granted by each Party to the other under this Agreement, in the event that (a) any Allergan RTGel Improvement is made by or on behalf of Allergan or any of its Affiliates or (b) any RTGel Improvement is made by or on behalf of UroGen or any of its Affiliates, in each case relating to, or that is otherwise necessary or useful for, the Manufacture of the RTGel Product during the Term (“New Manufacturing Technology”), such Party shall promptly disclose such New Manufacturing Technology to the other Party and shall, at the other Party’s request, perform technology transfer with respect to such New Manufacturing Technology in the same manner as provided in Section 5.2 (applied mutatis mutandis to Allergan, as applicable).
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, in the event that Licensor makes any invention, discovery, or improvement relating to the Manufacture of a Discovery Probody, a Discovery PDC or a Licensed Product after Licensor has conducted a technology transfer pursuant to Section 5.7.2, Licensor shall, promptly disclose such invention, discovery, or improvement to AbbVie, and shall, at AbbVie’s request and at AbbVie’s sole cost and expense, perform technology transfer with respect to such invention, discovery, or improvement in the same manner as provided in Section 5.7.2.
Subsequent Manufacturing Technology Transfer. During the applicable period approved by the JSC, in anticipation of the conclusion of the LogicBio Manufacturing Period with respect to the Lead Product, LogicBio and CANbridge will [**] (each, a “Designated CMO”) [**] is [**] to enable the Manufacture of the Lead Product, to the extent not previously [**] (the “Subsequent Manufacturing Technology Transfer,” and, together with the Initial Manufacturing Technology Transfer, each a “Manufacturing Technology Transfer”), and [**].
Subsequent Manufacturing Technology Transfer. Without limiting the foregoing, during the [†] following AbbVie’s request for the Manufacturing Technology Transfer pursuant to Section 5.5.2 (Manufacturing Technology Transfer Upon AbbVie’s Request), in the event that there is any invention, discovery or improvement included in the Licensor Know-How relating to the Manufacture of a Licensed Compound or Licensed Products developed, invented or reduced to practice, Licensor shall promptly disclose such invention, discovery or improvement to AbbVie and shall, at AbbVie’s reasonable request, and subject to Section 5.5.2(f) (Manufacturing Technology Transfer Upon AbbVie’s Request), perform technology transfer with respect to such invention, discovery or improvement in the same manner as provided in Section 5.5.2 (Manufacturing Technology Transfer Upon AbbVie’s Request).
